Most Read Articles
Natalia Reoutova, 3 days ago

Precision therapy for prostate cancer (PC) is becoming reality, with recent studies demonstrating efficacy of this approach in patients with metastatic castration-resistant PC (mCRPC) with certain DNA damage repair (DDR) alterations or PTEN loss.

Rationale and clinical evidence for the use of tumour-treating fields in the treatment of glioblastoma and other cancers

24 Apr 2020
Tumour-treating fields (TTFields) are a non-invasive anticancer treatment modality that utilizes low-intensity, intermediate-frequency (100–300 kHz), alternating electric fields delivered through transducer arrays placed around the tumour region to inhibit tumour cell division.  

These TTFields affect various charged and polar molecules within rapidly dividing cancer cells. Through interfering with the structure of microtubules and the movement of organelles during cell division, TTFields cause abnormal mitosis, leading to cell death, blocking of cell division or the formation of lethal chromosomal aberrations. 

Sponsored as a service to the medical profession by Zailab Optune.Editorial development by MIMS MedComms.The opinions expressed in this publication are not necessarily those of the editor, publisher or sponsor.Any liability or obligation for loss or damage howsoever arising is hereby disclaimed.© 2020 MIMS (Hong Kong) Limited. All rights reserved.No part of this publication may be reproduced by any process in any language without the written permission of the publisher
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 3 days ago

Precision therapy for prostate cancer (PC) is becoming reality, with recent studies demonstrating efficacy of this approach in patients with metastatic castration-resistant PC (mCRPC) with certain DNA damage repair (DDR) alterations or PTEN loss.